<DOC>
	<DOCNO>NCT02297139</DOCNO>
	<brief_summary>The purpose study continue provide dasatinib patient currently participate another dasatinib trial end option provide dasatinib .</brief_summary>
	<brief_title>Continuing Treatment Subjects Who Have Participated Prior Protocol Investigating Dasatinib</brief_title>
	<detailed_description />
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Participated complete previous dasatinib protocol ( include limit CA180056 , CA180363 CA180227 ) deem investigator derive benefit dasatinib define previous protocol Receiving dasatinib time signature inform consent Males Females , age 18 old All patient previously discontinue dasatinib study reason Any serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy History allergy dasatinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>